TESARO is an oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients. The Company intends to leverage the experience and competencies of its management team to identify, acquire and develop promising drug candidates; and to commercialize safer and more effective products for the treatment and support of cancer patients.
TESARO is developing rolapitant, a potent, selective neurokinin-1 receptor antagonist that has completed Phase 2 clinical testing for the prevention of chemotherapy-induced nausea and vomiting, and is advancing its ALK inhibitor program for oncology indications.
Type
Public
HQ
Waltham, US
Founded
2010
Size (employees)
446 (est)
TESARO was founded in 2010 and is headquartered in Waltham, US
Report incorrect company information

TESARO Office Locations

TESARO has an office in Waltham
Waltham, US (HQ)
3300 1000 Winter St
Show all (1)
Report incorrect company information

TESARO Financials and Metrics

TESARO Financials

TESARO's revenue was reported to be $44.82 m in FY, 2016 which is a 14039.7% increase from the previous period.
USD

Revenue (Q3, 2017)

142.8 m

Net income (Q3, 2017)

(25.3 m)

EBIT (Q3, 2017)

(22.1 m)

Market capitalization (5-Feb-2018)

3.3 b

Cash (3-Feb-2018)

521.3 m
TESARO's current market capitalization is $3.3 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

317 k44.8 m

Revenue growth, %

14040%

General and administrative expense

158.6 m

R&D expense

235.1 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Revenue

307 k36.6 m3.7 m3.1 m29.5 m142.8 m

General and administrative expense

4.5 m4.7 m5.6 m6.3 m11.2 m16.8 m22.8 m30 m36.2 m37.7 m69.3 m93 m

R&D expense

22.2 m28.1 m30.6 m29.9 m33.5 m38.9 m40.1 m52.6 m50.1 m60.8 m66.1 m71.4 m

Operating expense total

28.6 m49.8 m37.1 m36.2 m44.8 m56.7 m62.8 m87.2 m91.1 m101.3 m136.3 m178 m164.9 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

130.3 m256.9 m230.1 m785.9 m

Accounts Receivable

679 k5.3 m

Inventories

1.1 m14.7 m

Current Assets

134.3 m258.6 m236.5 m814.8 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Cash

156.4 m180.3 m151.1 m295.9 m399.1 m354.4 m302.5 m314.5 m320.2 m647.3 m672.2 m507.9 m521.3 m

Accounts Receivable

1.1 m1.1 m510 k3.2 m6.1 m23.1 m27.7 m

Inventories

476 k6 m8.4 m12.2 m15.6 m28.3 m50.5 m

Current Assets

157.9 m183.6 m154.1 m297.7 m401.3 m357.2 m308.5 m325.7 m337.8 m670.1 m707.6 m582.4 m621.7 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(92.4 m)(171 m)(251.4 m)(387.5 m)

Depreciation and Amortization

179 k349 k1 m3.1 m

Inventories

(1.1 m)14.7 m

Accounts Payable

(1.3 m)4.2 m1.9 m5.2 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017

Net Income

(28.6 m)(49.8 m)(37.1 m)(36.2 m)(48.5 m)(60.6 m)(66.6 m)(90.8 m)(58.4 m)(101.2 m)(136.7 m)(25.3 m)

Inventories

476 k6 m8.4 m12.2 m15.6 m50.5 m

Accounts Payable

2.8 m4.1 m5.7 m9.6 m5.6 m12.3 m14 m3.3 m10.3 m6 m
USDY, 2017

Revenue/Employee

320.1 k

Financial Leverage

1.7 x
Show all financial metrics

TESARO Operating Metrics

FY, 2016

Countries

7

Patent Portfolios

3

Products

2
Show all operating metrics
Report incorrect company information